Infectious Diseases Protocols / Clinical Studies

For information on these and other studies, referring physicians may e-mail  or call toll free physician referral line, 1-888-226-4343. If you are not a physician, please e-mail for information on St. Jude studies.


A phase 3, Open-Label, Multicenter Study of the Safety/Tolerability and Efficacy of Brincidofovir (CMX001) for the Prevention of Adenovirus (AdV) Disease in Subjects with Asymptomatic AdV Infection at Risk of Progression and for the Treatment of Subjects with Localized or Disseminated Adenovirus Disease

For: adenovirus


Non St. Jude Protocols


A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of DAS181 in Immunocompromied Subjects with Lower Respiratory Tract ParaInfluenza (PIV) Infection on Supplemental Oxygen

For: Parainfluenza virus in immunocompromised patients


A Phase 2/3 multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (BR) Containing a Ritonavir-Boosted Protease Inhibitor (PI/r) in HIV-1 Infected, Antiretroviral Treatment-Experienced Pediatric Subjects

For: HIV


An Open-Label, Multi-Center, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Zanamivir in the Treatment of Hospitalized Adult, Adolescent and Pediatric Subjects with Confirmed Influenza Infection

For: Influenza


A Phase 2/3, Open-Label Multi- Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a Tenofovir Disoproxil Fumarate (TDF)-Containing Regimen, Initial Version, June 23, 2014



A Phase 2/3, Open-Label Study and Efficacy of E/C/F/TAF in HIV-1 Infected Virologically Suppressed Adolescents, Initial Version, June 25, 2014 (GS-US-292-1515)



Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK1349572, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents

For: Human Immunodeficiency Virus